Editorial: A Is for Amyloid.
作者信息
Selkoe D J
机构信息
D.J. Selkoe, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA,
出版信息
J Prev Alzheimers Dis. 2020;7(3):140-141. doi: 10.14283/jpad.2020.27.
Abstract
摘要
相似文献
1
Editorial: A Is for Amyloid.
J Prev Alzheimers Dis. 2020;7(3):140-141. doi: 10.14283/jpad.2020.27.
2
Antibody drugs for Alzheimer's show glimmers of promise.
Nature. 2015 Jul 30;523(7562):509-10. doi: 10.1038/nature.2015.18031.
3
Fluid Biomarker Changes After Amyloid-β-Targeting Drugs.
JAMA Neurol. 2024 Jun 1;81(6):579-581. doi: 10.1001/jamaneurol.2024.1103.
4
Revisiting FDA Approval of Aducanumab.
N Engl J Med. 2021 Aug 26;385(9):769-771. doi: 10.1056/NEJMp2110468. Epub 2021 Jul 28.
5
Alzheimer disease: Anti-Aβ antibody treatment shows promise in Alzheimer disease.
Nat Rev Neurol. 2016 Oct;12(10):554-5. doi: 10.1038/nrneurol.2016.144. Epub 2016 Sep 16.
6
The search for Alzheimer disease therapeutics - same targets, better trials?
Nat Rev Neurol. 2020 Nov;16(11):597-598. doi: 10.1038/s41582-020-00414-3.
7
Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.
Bratisl Lek Listy. 2018;119(4):201-204. doi: 10.4149/BLL_2018_037.
8
Alzheimer's drugs take a new tack.
Nature. 2012 Sep 6;489(7414):13-4. doi: 10.1038/489013a.
9
Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease.
J Neurosci. 2017 Apr 26;37(17):4430-4432. doi: 10.1523/JNEUROSCI.0420-17.2017.
10
Amyloid Cascade into Clarity.
Immunity. 2016 Oct 18;45(4):717-718. doi: 10.1016/j.immuni.2016.10.006.
引用本文的文献
1
The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention.
Int J Mol Sci. 2024 Feb 27;25(5):2727. doi: 10.3390/ijms25052727.
2
Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses.
Aging Dis. 2024 Feb 1;15(1):43-73. doi: 10.14336/AD.2023.0608.
3
Cerebral Aβ deposition in an Aβ-precursor protein-transgenic rhesus monkey.
Aging Brain. 2022;2. doi: 10.1016/j.nbas.2022.100044. Epub 2022 Jun 17.
4
Aβ Influx into the Blood Evoked by Different Blood Aβ Removal Systems: A Potential Therapy for Alzheimer's Disease.
Neuropsychiatr Dis Treat. 2021 Jul 13;17:2291-2308. doi: 10.2147/NDT.S317104. eCollection 2021.
5
Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression.
Int J Mol Sci. 2021 Jun 14;22(12):6355. doi: 10.3390/ijms22126355.
6
Building clinically relevant outcomes across the Alzheimer's disease spectrum.
Alzheimers Dement (N Y). 2021 Jun 26;7(1):e12181. doi: 10.1002/trc2.12181. eCollection 2021.
7
Aβ Plaques.
Free Neuropathol. 2020;1:31. doi: 10.17879/freeneuropathology-2020-3025. Epub 2020 Oct 30.
8
Vaccination against β-Amyloid as a Strategy for the Prevention of Alzheimer's Disease.
Biology (Basel). 2020 Nov 27;9(12):425. doi: 10.3390/biology9120425.
9
Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Alzheimers Res Ther. 2020 Aug 12;12(1):95. doi: 10.1186/s13195-020-00663-w.
本文引用的文献
1
The Future of Anti-Amyloid Trials.
J Prev Alzheimers Dis. 2020;7(3):146-151. doi: 10.14283/jpad.2020.24.
2
An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer's disease.
Nat Commun. 2018 Jul 11;9(1):2676. doi: 10.1038/s41467-018-05068-w.
3
Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls.
Ann Neurol. 2013 Jan;73(1):104-19. doi: 10.1002/ana.23748. Epub 2012 Dec 7.
4
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.
Nat Med. 2008 Aug;14(8):837-42. doi: 10.1038/nm1782. Epub 2008 Jun 22.
Zotero 插件